Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Medica

Atypical Chronic Myeloid Leukemia

Initial criteria

  • patient has a CSF3R mutation OR patient has a Janus Associated Kinase 2 (JAK2) mutation

Approval duration

1 year